LS9

LS9 and Procter & Gamble Launch Sustainable Chemicals Partnership

LS9 and Procter & Gamble Launch Sustainable Chemicals Partnership

May 19, 2009

Confirms P&G’s Commitment to Sustainable Innovation

Accelerates LS9’s Entry into the Consumer Product Chemicals Market

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO and Duncan Higgons as COO

Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO and Duncan Higgons as COO

May 27, 2009

Industry Leaders Bring Deep Oncology and Company Building Experience

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs

Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs

June 2, 2009

LEXINGTON, Mass. & LONDON -- Concert Pharmaceuticals and GlaxoSmithKline (NYSE: GSK) announced today that they will collaborate to develop and commercialize deuterium-containing medicines. The deal includes three of Concert’s research and development programs; namely, CTP-518, a protease inhibitor for the treatment of HIV expected to enter Phase I clinical trials in the second half of 2009, a preclinical compound for chronic renal disease, and a third research product in Concert’s pipeline.

TARIS Biomedical, Inc.

TARIS Biomedical Launches with $15 Million in Funding to Develop Innovative Drug-Device Therapies

TARIS Biomedical Launches with $15 Million in Funding to Develop Innovative Drug-Device Therapies

June 24, 2009

LEXINGTON, Mass. - (Business Wire) TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, launched today and announced it has secured $15 million in Series A financing. Leading venture capital firms Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners co-led the investment in TARIS, which was founded by internationally renowned scientists from the Massachusetts Institute of Technology (MIT), Michael Cima, Ph.D.

VisEn Medical, Inc.

VisEn Launches New Cat-K FAST™ Fluorescence Molecular Imaging Agent

VisEn Launches New Cat-K FAST™ Fluorescence Molecular Imaging Agent

July 7, 2009

Expands VisEn’s Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Breakthrough Readouts of Cathepsin-K Biomarkers in Research and Drug Development

BG Medicine, Inc.

Humana and BG Medicine Enroll More Than 6,800 Participants in BioImage Study Focused on Heart Attack Prediction

Humana and BG Medicine Enroll More Than 6,800 Participants in BioImage Study Focused on Heart Attack Prediction

July 7, 2009

Humana health-plan members in Chicago and South Florida volunteered to participate in study

Helicos BioSciences Corporation

Helicos BioSciences Announces Publication in Nature Biotechnology

Helicos BioSciences Announces Publication in Nature Biotechnology

July 7, 2009

Single molecule sequencing provides first amplification-free, unbiased view of a transcriptome

Accuri Cytometers, Inc.

Accuri Cytometers Completes $4 Million Series D Financing

Accuri Cytometers Completes $4 Million Series D Financing

July 13, 2009

Funds Will Provide Additional Working Capital to Support Strong Market Demand for Accuri C6 Flow Cytometer® System and Accuri CSampler™

Joule Unlimited, Inc.

Joule Biotechnologies Introduces Revolutionary Process for Producing Renewable Transportation Fuels

Joule Biotechnologies Introduces Revolutionary Process for Producing Renewable Transportation Fuels

July 27, 2009

Two years into development, innovative startup enables path to energy independence; Unveils proprietary production system capable of supplying unlimited quantities of renewable fuel at costs competitive with fossil fuels

VisEn Medical, Inc.

VisEn Molecular Imaging Technology Enables Key Insights into Newly Discovered Biologic Pathway Published in Science

VisEn Molecular Imaging Technology Enables Key Insights into Newly Discovered Biologic Pathway Published in Science

July 30, 2009

BEDFORD, MA (July 30, 2009)-- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that scientists reporting in the July 31 issue of SCIENCE have discovered a key disease-related biologic pathway using an integrated and innovative array of in vitro readouts and advanced in vivo imaging technologies. The newly reported biologic pathway relates to monocyte deployment from the spleen to inflammatory sites, including myocardial infarction.